Spyre Therapeutics, Inc. (SYRE) Financial Analysis & Valuation | Quarter Chart
Spyre Therapeutics, Inc. (SYRE)
SYREPrice: $90.16
Fair Value: 🔒
🔒score
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for t... more
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeut... more
Description
Shares
| Market Cap | $5.45B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Cameron Turtle |
| IPO Date | 2016-04-07 | CAGR | — |
| Employees | 73 | Website | www.spyre.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SYRE chart loading...
Fundamentals
Technicals
| Enterprise Value | $18.35B | P/E Ratio | -43.35 |
| Forward P/E | -28.82 | PEG Ratio | — |
| P/S Ratio | 73.67 | P/B Ratio | 56.94 |
| P/CF Ratio | -205.56 | P/FCF Ratio | -35.88 |
| EPS | $-2.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | -2.56% | Profit Margin | -1.98% |
| ROE | -0.31% | ROA | -0.23% |
| ROCE | -0.34% | Current Ratio | 8.97 |
| Quick Ratio | 8.97 | Cash Ratio | 1.14 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | 33.36 | Piotroski Score | 2 |